Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
reboxetine + oxybutynin (Flinders University)
- Development stage
- Unknown
- Lead developer
- Flinders University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AD173 is an investigational oral combination therapy consisting of reboxetine, a selective norepinephrine reuptake inhibitor (NRI), and oxybutynin, an anticholinergic agent. Developed by researchers at the Adelaide Institute for Sleep Health (AISH) at Flinders University, the combination is designed to treat obstructive sleep apnoea (OSA) by targeting the underlying neuromuscular and physiological causes of the condition. Reboxetine is intended to increase the activity of the upper airway dilator muscles (such as the genioglossus) during sleep, while oxybutynin acts to stabilize breathing and increase the respiratory arousal threshold, reducing the frequency of awakenings caused by respiratory events. Clinical studies conducted at Flinders University have evaluated the efficacy of AD173 in improving sleep efficiency and reducing the severity of OSA symptoms.
- Other names
- reboxetine and oxybutynin combination
02
Targets
M1 (Muscarinic acetylcholine receptor M1)CHRM3 (M3)DAT (Dopamine plasma membrane transport protein)CHRM2 (M2)SERT (Sodium-dependent serotonin transporter)CHRM5 (M5)NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on reboxetine + oxybutynin (Flinders University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on reboxetine + oxybutynin (Flinders University).